Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
Nephrology has benefited from conducting increasingly large high-quality trials in the last 5- 10 years. In addition to the long-standing known benefits of renin-angiotensin system inhibitors, we now have multiple pharmacotherapies that provide kidney and/or cardiovascular protection for certain typ...
Hauptverfasser: | Zhu, D, Staplin, N, Haynes, R, Herrington, W, Judge, P |
---|---|
Format: | Journal article |
Sprache: | English |
Veröffentlicht: |
Oxford University Press
2025
|
Ähnliche Einträge
Ähnliche Einträge
-
Kidney disease trials for the 21st century: innovations in design and conduct
von: Herrington, W, et al.
Veröffentlicht: (2019) -
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
von: Mayne, K, et al.
Veröffentlicht: (2024) -
Renoprotective effect of pentoxifylline in advanced chronic kidney disease
von: Chih-Chin Kao
Veröffentlicht: (2015-01-01) -
Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
von: Preiss, D, et al.
Veröffentlicht: (2022) -
The prevention and management of chronic kidney disease among patients with metabolic syndrome
von: Zhu, D, et al.
Veröffentlicht: (2025)